Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ZGR regimen limited-course regimen was designed to combine three targeted agents, zanubrutinib, obinutuzumab (a third-generation CD20 monoclonal antibody), and lenalidomide, to deepen the depth of remission in patients with new-diagnosis CLL/SLL, with a view to achieving the goal of discontinuation of the drug and long-term remission after discontinuation of the drug, and prolonging the PFS, and at the same time, the regimen no longer includes cytotoxic chemotherapeutic agents, such as fludarabine and cyclophosphamide, which improves the CLL/ SLL patients' treatment tolerance, and can eliminate the treatment limitation for elderly or poorly tolerated CLL/SLL patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06544785

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

RECRUITING PHASE2

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

NCT06849713

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma (SLL)

RECRUITING PHASE2

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

NCT05287984

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Newly Diagnosed

UNKNOWN PHASE2

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

NCT07261163

Mantle Cell Lymphoma

NOT_YET_RECRUITING PHASE2

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT03206918

Relapsed or Refractory Chronic Lymphocytic Leukemia Relapsed or Refractory Small Lymphocytic Lymphoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BTK inhibitor monotherapy for CLL/SLL can obtain 80-90% ORR and give patients long-term survival, but most patients only obtain PR efficacy, even after up to 7-8 years of continuous treatment, the proportion of patients with CR can only be improved from less than 10% to about 30%, and it is very difficult for any patient to achieve MRD negativity, so it is determined that the mode of treatment of BTK inhibitor monotherapy is long-term continuous administration for tumor control. In order to change this pattern of long-term continuous treatment, and to shorten the long-term continuous treatment to a limited cycle of treatment, it is necessary to deepen the depth of remission by combining the treatment with other mechanisms of drugs, or even to achieve MRD-negativity in order to realize the discontinuation of the drug.

Lenalidomide is an oral immunomodulatory drug with direct antitumor effects and indirect antitumor effects by acting on a variety of immune cells in the tumor microenvironment. Lenalidomide alone, in combination with CD20 monoclonal antibody (rituximab), or (and) BTK inhibitors for the treatment of R/R CLL/SLL has shown therapeutic responses, with the best response to triple therapy of lenalidomide in combination with rituximab and BTK inhibitors. combination therapy showed the best response.

The ZGR limited-course regimen that combines zanubrutinib, obinutuzumab, and lenalidomide in the treatment of patients with primary diagnosis of CLL/SLL, which can deepen the depth of remission, with a view to achieving the goal of discontinuation of the drug and long-term remission after discontinuation of the drug, and prolonging the PFS, and at the same time, the regimen are removed cytotoxic chemotherapeutic agents, such as fludarabine, to increase the tolerance of the treatment in patients with CLL/SLL, and can eliminate the need for treatment of elderly or poorly tolerated patients with CLL/SLL. treatment limitations in poorly tolerated CLL/SLL patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Newly Diagnosed

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ZGR regimen

Dose Escalation lenalidomide combined with Zanubrutinib and Obinutuzumab (Dose escalation will occur using a 3+3 design)

Recommended phase II dose (RP2D) lenalidomide combined with Zanubrutinib and Obinutuzumab

Group Type EXPERIMENTAL

Zanubrutinib

Intervention Type DRUG

160mg bid/d, from C1 to CR and MRD-negative or C24

Lenalidomide

Intervention Type DRUG

From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24

Obinutuzumab

Intervention Type DRUG

1000 mg C1, d1/d8/15; 1000 mg C2-6, d1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zanubrutinib

160mg bid/d, from C1 to CR and MRD-negative or C24

Intervention Type DRUG

Lenalidomide

From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24

Intervention Type DRUG

Obinutuzumab

1000 mg C1, d1/d8/15; 1000 mg C2-6, d1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1） Patients were not categorized by gender ，Age ≥18;
* 2） Confirmed diagnosis of CLL or SLL;
* 3）Patients must be untreated, or not undergoing standardized treatment for the first time, under the following conditions:
* a) Not treated with fludarabine-containing or bendamustine-containing or rituximab-containing regimens;
* b) Have not been treated with the application of chlorambucil, or have applied chlorambucil for less than 4 weeks (alone or in combination with adrenal glucocorticoids);
* (c) If the above treatment has been applied, it must be stopped for 2 weeks before enrollment in the group to start the treatment.
* 4） Indications for treatment of CLL/SLL include, inter alia (at least one of the following conditions is met)

1. Evidence of progressive bone marrow failure: as evidenced by progressive decrease in hemoglobin and/or platelets;
2. Giant spleen (e.g., \>6 cm below the left costal margin) or symptomatic splenomegaly;
3. Giant lymph node enlargement (e.g., longest diameter \>10 cm) or symptomatic lymph node enlargement;
4. Progressive lymphocytosis, e.g., \>50% lymphocytosis within 2 months, or lymphocyte doubling time (LDT) \<6 months. When initial lymphocytes are \<30 x 10\^9/L, LDT alone cannot be used as a therapeutic indication;
5. CLL/SLL resulting in symptomatic organ dysfunction (e.g., skin, kidney, lung, spine, etc.)
6. Autoimmune hemolytic anemia (AIHA) and/or immune thrombocytopenia (ITP) that does not respond well to corticosteroids or other standard therapy;
7. Presence of at least one of the following disease-related symptoms: i) weight loss ≥10% without apparent cause within the previous 6 months; ii) severe fatigue (e.g., ECOG physical status ≥2; inability to perform routine activities); iii) temperature \>38°C for ≥2 weeks without evidence of infection; iv) nocturnal night sweats for \>1 month without evidence of infection;
* 5） ECOG≤2
* 6\) Major organ function within 7 days prior to treatment, meet the following criteria: routine blood test criteria: platelets ≥30×10\^9/L; biochemical tests need to meet the following criteria: total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤2.5 ULN; creatinine clearance ≥ 30 ml/min; and cardiac Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ low limit of normal (50%);
* 7\) Male and female patients of childbearing age agree to use reliable contraception throughout the study period and for 4 weeks after the end of study treatment;
* 8\) Patients need to have an expected survival of ≥ 6 months;
* 9\) Patients need to voluntarily participate in this study by signing an informed consent form.

Exclusion Criteria

* Patients who met any of the following criteria were excluded from the study:
* (1) Malignancies other than CLL/SLL (including active CNS lymphoma) have been diagnosed or treated within the past year;
* (2) There has been clinical evidence of Richter transformation;
* (3) Non-lymphoma-related hepatic and renal impairment: alanine aminotransferase (ALT) \> 3 times the upper limit of normal, alanine transaminase (AST) \> 3 times the upper limit of normal, total bilirubin (TBIL) \> 2 times the upper limit of normal, and serum creatinine clearance \< 30 ml/min;
* (4) Other serious medical disorders that would interfere with the study (e.g., uncontrolled diabetes mellitus, gastric ulcers, grade 3 or 4 atrial fibrillation or persistent atrial fibrillation of any grade, other serious cardiorespiratory diseases, etc.). The judgmental decision is vested in the investigator;
* (5) Patient who had infected with Human Immunodeficiency Virus (HIV) or active Hepatitis B Virus (HBV) infection, or any uncontrolled active systemic infection requiring intravenous antibiotics;
* (6) Clinically manifested CNS dysfunction or invasion of the center;
* (7) Patients who have undergone a major surgical procedure (excluding lymph node biopsy) within the last 14 days or who require a major surgical procedure in anticipation of treatment;
* (8) Inability to swallow capsules or suffering from malabsorption syndromes, disorders significantly affecting gastrointestinal function, having undergone gastric or small bowel resection, symptomatic inflammatory bowel disease or ulcerative colitis, and partial or complete intestinal obstruction.
* (9) Requires treatment with potent cytochrome P450 (CYP) 3A inhibitors;
* (10) Pregnant or lactating women of childbearing age who are not using contraception;
* (11) Patients with clinically significant cardiovascular abnormalities (New York Heart Association (NYHA) classification: III/IV), myocardial infarction within 6 months prior to enrollment, malignant arrhythmias (including QTC ≥ 480 ms), poorly controlled blood pressure (systolic ≥ 150 mmHg, diastolic ≥ 100 mmHg) despite the use of antihypertensive medications, and uncontrolled angina;
* (12) Persistent uncontrolled bleeding;
* (13) History of life-threatening hemorrhage, especially from irreversible causes;
* (14) Need for high doses of several anticoagulants that cannot be briefly discontinued;
* (15) Thrombotic events within three months of treatment initiation;
* (16) Patients with severe hypersensitivity to the active ingredient of the study drug or to any of its excipients;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No